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Health services use among children
diagnosed with medium-chain acyl-CoA
dehydrogenase deficiency through
newborn screening: a cohort study in
Ontario, Canada
Maria D. Karaceper1, Sara D. Khangura1, Kumanan Wilson1,2,24, Doug Coyle1, Marni Brownell3, Christine Davies5,
Linda Dodds6, Annette Feigenbaum7, Deshayne B. Fell1,8,11, Scott D. Grosse9, Astrid Guttmann10,11,12,13,
Steven Hawken1,2,11, Robin Z. Hayeems10,13, Jonathan B. Kronick7, Anne-Marie Laberge14, Julian Little1,
Aizeddin Mhanni15, John J. Mitchell16, Meranda Nakhla16, Murray Potter17,18, Chitra Prasad19,
Cheryl Rockman-Greenberg15, Rebecca Sparkes20, Sylvia Stockler21,22, Keiko Ueda21, Hilary Vallance22,23,
Brenda J. Wilson25, Pranesh Chakraborty5,8,4, Beth K. Potter1,8,11* and in collaboration with the Canadian Inherited
Metabolic Diseases Research Network (CIMDRN)

Abstract
Background: We describe early health services utilization for children diagnosed with medium-chain acyl-CoA
dehydrogenase (MCAD) deficiency through newborn screening in Ontario, Canada, relative to a screen negative
comparison cohort.
Methods: Eligible children were identified via newborn screening between April 1, 2006 and March 31, 2010. Agestratified rates of physician encounters, emergency department (ED) visits and inpatient hospitalizations to March
31, 2012 were compared using incidence rate ratios (IRR) and incidence rate differences (IRD). We used negative
binomial regression to adjust IRRs for sex, gestational age, birth weight, socioeconomic status and rural/urban
residence.
Results: Throughout the first few years of life, children with MCAD deficiency (n = 40) experienced statistically
significantly higher rates of physician encounters, ED visits, and hospital stays compared with the screen negative
cohort. The highest rates of ED visits and hospitalizations in the MCAD deficiency cohort occurred from 6 months
to 2 years of age (ED use: 2.1–2.5 visits per child per year; hospitalization: 0.5–0.6 visits per child per year), after
which rates gradually declined.
Conclusions: This study confirms that young children with MCAD deficiency use health services more frequently
than the general population throughout the first few years of life. Rates of service use in this population gradually
diminish after 24 months of age.
Keywords: Newborn screening, Inherited metabolic diseases, Health service utilization, Medium-chain acyl-CoA
dehydrogenase deficiency
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Background
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a fatty acid beta-oxidation disorder with an estimated birth prevalence of approximately 1:5000 to 1:20,000
in North America and northern Europe [1–4]. Patients are
at risk of acute metabolic decompensation during times of
physiological stress, such as prolonged fasting and viral illness, with high morbidity and risk of mortality [5, 6]. Early
diagnosis is critical because most adverse outcomes are preventable with long-term therapy that includes avoidance of
fasting as well as provision of rapidly accessible carbohydrates and close medical monitoring during intercurrent
illness [4, 6]. Preventive parenteral glucose is often administered in the emergency department (ED) during high-risk
periods. Acute crises require ED management and sometimes inpatient hospitalization.
Timely diagnosis of MCAD deficiency through newborn
blood spot screening followed by appropriate management dramatically reduces the risks of acute metabolic crises, early death, and long-term disability, although specific
estimates vary across studies [7–10] and some infants with
MCAD deficiency experience severe and potentially fatal
early neonatal illness prior to the availability of newborn
screening results [11]. Multiple economic studies have
concluded that newborn screening for MCAD deficiency
appears cost-effective [10, 12–17]. A Dutch study calculated that the avoided costs of institutional care for children with neurological disability caused by late-diagnosed
MCAD deficiency offset almost half the cost of screening
[12]. Similarly, simulations from a cost-effectiveness analysis that incorporated primary data from a US cohort predicted that the majority of the costs associated with
newborn screening for MCAD deficiency would be offset
by the avoidance of severe adverse outcomes [16].
Screening has also led to a different spectrum of
observed cases, with a higher proportion of children with
MCAD deficiency identified by newborn screening predicted to have milder forms of disease, relative to clinically
identified cases [18–21]. A greater understanding of how
MCAD deficiency impacts healthcare utilization among
children diagnosed asymptomatically through newborn
screening programs can support healthcare providers in
communicating with families about the expected clinical
course and health service needs of their children.
Newborn Screening Ontario is Canada’s largest newborn
screening program and coordinates screening for approximately 140,000 babies born each year, with MCAD deficiency having been added to the screening panel in April,
2006 [1]. The availability of population-based data that captures information about the use of health services for all
Ontario residents provides a unique opportunity to investigate healthcare utilization patterns for young children with
MCAD deficiency detected by population-based screening
relative to young children with negative newborn screening
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results. We hypothesized that age-stratified rates of healthcare use would be modestly higher among children with
MCAD deficiency than among children in a screen-negative comparison cohort over the same time period. Because
we had data on outcomes for only those children identified
through newborn screening, we were unable to calculate
the reduction in healthcare use relative to children with
MCAD deficiency born prior to the introduction of expanded newborn screening in Ontario.

Methods
Study population and data sources

We initially included all children who were born in
Ontario and received newborn screening between April 1,
2006 and March 31, 2010. Individuals were excluded from
the study if they were ineligible for public health insurance
coverage at the time of birth (e.g., non-residents) or died
within 24 h following birth (in Ontario, blood spot samples for newborn screening are considered valid when collected at or later than 24 h of age).
The cohort of children with MCAD deficiency included
screen-identified children with a diagnosis confirmed
through follow-up evaluation [1]. Ontario newborns who
screen positive are referred to one of five regional
newborn screening treatment centres based at pediatric
tertiary care hospitals. The treatment centre and the
infant’s primary healthcare provider collaborate to contact
the parents and arrange diagnostic testing, which typically
includes plasma acylcarnitine profiling, urine organic acids
analysis, and testing for mutations in the ACADM gene
[1]. Medical staff at Newborn Screening Ontario review
and document the diagnostic results reported by the treatment centres. Infants are considered to have a diagnosis of
MCAD deficiency if they have a disease-associated genotype (e.g., homozygous or compound heterozygous for the
c.985A > G mutation or for any other mutation associated
with the disease), and/or persistent abnormal plasma acylcarnitines, and/or hexanoylglycine detected on urine organic acids analysis. The treatment centre is responsible
for ongoing follow-up and management for affected children. There is not a provincial treatment protocol for
MCAD deficiency management in Ontario and metabolic
physicians tailor care based on patient age and disease
characteristics as well as sociodemographic factors [22].
Treatment centres typically provide parental and primary
care physician education about fasting avoidance, ‘sick day’
protocols for maintaining glucose levels during illness,
and recommendations for medical monitoring during
illness; the latter may involve telephone or in-clinic care
by treatment centre staff and/or emergency department
letters to ensure rapid and appropriate care during at-risk
periods. The screen-negative comparison cohort included
all children with negative newborn screening results for all
screened disorders.
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Newborn screening short term follow up data were
reviewed by Newborn Screening Ontario medical staff to
confirm the final diagnosis, which was linked to the provincial healthcare patient registry at the ICES as well as to administrative databases encompassing health service
encounters from April 1, 2006 through March 31, 2012.
These datasets were linked using unique encoded identifiers and analyzed at ICES. Physician encounter data were
identified using the Ontario Health Insurance Plan (OHIP)
Claims Database, which captures services provided by Ontario physicians who bill OHIP on a fee-for-service basis
and services provided by other Ontario physicians,
dependent on their model of payment [23]. ED visit data
were obtained from the Canadian Institute for Health Information (CIHI) National Ambulatory Care Reporting System [24]. Inpatient hospitalization data were retrieved from
the CIHI Discharge Abstract Database [25].
Covariates

Covariates from the newborn hospital record included
sex, birth weight, gestational age, and season of birth.
Children were grouped into low (< 2500 g) and normal/
high (≥ 2500 g) birth weight categories and were dichotomized as preterm (< 37 weeks’ gestation) or term/post-term (≥ 37 weeks). Season of birth was categorized as
January–April, May–August, or September–December.
We used neighborhood-level income quintiles as a proxy
measure of socioeconomic status, grouping the two lowest
and three highest quintiles to define lower and higher socioeconomic status. Quintiles were based on income data
from the 2006 Canadian Census at the “dissemination
area” level (populations of approximately 400–700 persons), linked to the postal code of a child’s residence at the
time of birth [26, 27]. We used the Rurality Index for Ontario (RIO) to assign urban-rural status to each child’s residence at birth [28]. The RIO is based on population size,
density, and travel time to high-level healthcare centres;
we used a RIO score of ≥40 to define a rural community,
corresponding with the cutoff used to establish rural physician eligibility [29].
Utilization outcomes

Outcomes were health service encounters, including physician encounters, ED visits, and hospitalizations during
the study period. If a child had multiple billed procedures
on the same day with the same physician, these were considered as one physician encounter. However, if a child
saw multiple physicians on the same day, each was considered a separate physician encounter. Physician encounters
excluded laboratory billings but included physician-billed
encounters that took place in any location, including
in-hospital care. Each ED visit or inpatient hospitalization
was considered a separate encounter. If an ED visit led to
a hospital admission, this would be counted as both an
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ED encounter and an inpatient hospitalization so that
both of these outcomes, which were analyzed separately,
would be true reflections of the frequency of use of the respective services.
Statistical analysis

We separately summed physician encounters, ED visits
and hospitalizations for each child. We calculated each
child’s length of follow-up as the time between date of
birth and the earliest end points among the following: date
of death, date of OHIP eligibility loss (mainly related to
emigration from Ontario), or the end of study follow-up
(i.e., March 31, 2012). Age-stratified rates were calculated
to describe healthcare use in each cohort. Incidence rate
ratios (IRR) were calculated to compare healthcare use in
the MCAD deficiency and screen negative cohorts on a
relative scale. Incidence rate differences (IRD) were used
to compare the cohorts on an absolute scale (i.e., taking
into account the underlying frequency of healthcare
visits), in order to provide an estimate of the number of
additional visits that parents and providers may expect
among children with MCAD deficiency in each age group.
Counts of fewer than 6 participants could not be reported
in accordance with privacy policies.
Using the Vuong test as a criterion [30], we selected
negative binomial regression to calculate IRRs for health
service use comparing the MCAD deficiency and screen
negative cohorts while adjusting for all covariates (sex,
birth weight, gestational age, season of birth, socioeconomic status, rural/urban residence at birth). Influential
outlying observations were identified [31, 32] and truncated to the 99th percentile. Models were stratified by age
at the time of the visit (< 1 year of age and ≥ 1 year of age).
All statistical analyses were performed using SAS® software version 9.3 (SAS Institute, North Carolina, USA).

Results
Study population

Forty children were diagnosed with MCAD deficiency
through newborn screening during the study period in
Ontario and no children who screened negative were later
diagnosed with MCAD deficiency (i.e., there were no
known missed cases from the screening program). The
screen-negative comparison cohort consisted of 545,355
children. Children with MCAD deficiency were more
likely to live in rural communities relative to the comparison cohort (Table 1). No other statistically significant differences were observed between cohort characteristics.
Age-specific rates of healthcare utilization
Physician encounters

Relative to other age ranges, children in both cohorts experienced their highest rates of physician encounters
from birth to 6 months of age, at 24.8 encounters per
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Table 1 Geographic and sociodemographic characteristics of
the study population
Study Cohort
MCAD deficiency,
n (%) (n = 40)

Screen negative,
n (%) (n = 545,355)

Male

20 (50.0)

279,638 (51.3)

Female

20 (50.0)

265,717 (48.7)

Sex

Season of Birth
January – April

12 (30.0)

177,918 (32.6)

May – August

16 (40.0)

192,896 (35.4)

Sept. – Dec.

12 (30.0)

174,541 (32.0)

< 2500 g

< 6 (≤12.5)

33,027 (6.1)

≥ 2500 g

35–40 (≥87.5)

508,466 (93.9)

a

Birth weight

Gestational agea
< 37 weeks

< 6 (≤12.5)

42,235 (7.9)

≥ 37 weeks

35–40 (≥87.5)

489,232 (92.1)

‘Lower’

16 (40.0)

232,269 (42.8)

‘Higher’

24 (60.0)

310,003 (57.2)

Rural

6 (15.0)

34,111 (6.3)

Urban

34 (85.0)

505,236 (93.7)

Socioeconomic status

Urban-rural statusb

a

Results are suppressed for cell sizes < 6
b
P < 0.05 for difference in proportion in the MCADD cohort versus the screen
negative comparison cohort

child per year (an average of 12.4 encounters per child
over the 6 month period) in the MCAD deficiency cohort, and 21 encounters per child per year (10.5 encounters per child over the 6 month period) in the screen
negative comparison cohort (Fig. 1). Rates of physician
encounters gradually diminished with increasing age in
both groups; after age two, rates were 7.2–7.5 encounters per child per year in the MCAD deficiency cohort,
and five encounters per child per year in the screen
negative cohort. Across all age categories, children with
MCAD deficiency experienced statistically significantly
higher rates of physician encounters compared to the
screen negative group, both on a relative scale, as
reflected by the IRR, and on an absolute difference scale,
as reflected by the IRD (Table 2). For example, from
birth to 6 months of age, children with MCAD deficiency experienced physician encounters approximately
1.2 times more frequently than those with negative
newborn screening results (95% confidence interval,
1.1–1.3); on an absolute scale, this reflected approximately 4.2 more encounters per child per year (95% confidence interval, 2.1–6.4), or an average of 2.1 additional
physician encounters per child with MCAD deficiency
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during that 6 month period. Beyond the first 6 months
of age, age–specific rates of physician encounters in the
MCAD deficiency cohort ranged from 1.3 to 1.7 times
higher than the corresponding rates in the screen negative cohort, reflecting an average of 2.0 to 5.8 additional
encounters per child per year.
ED visits

Children with MCAD deficiency experienced the highest
rates of ED visits between the ages of 6 months and
2 years, with the peak rate occurring between six and
12 months, at 2.5 visits per child per year (i.e., approximately 1.3 visits to the ED for each child during that
6 month period) (Fig. 1). The most commonly documented reasons prompting ED visits among children with
MCAD deficiency were nausea with vomiting, fever, and
cough. In contrast, children in the screen negative cohort
experienced a relatively stable rate of ED visits from birth
to 2 years of age (0.8–0.9 visits per child per year), with no
peak during the six- to 12-month age period. Similar to
the cohort of children with MCAD deficiency, in the
screen negative cohort, the most commonly documented
reasons for ED visits were fever, cough, and nausea with
vomiting. Both cohorts experienced gradually lower rates
of ED visits after 2 years of age.
On a relative (IRR) scale, children with MCAD deficiency
experienced a higher frequency of ED visits compared with
the screen negative cohort during the entire follow-up
period; the highest IRR, from six to 12 months of age, indicated a visit rate that was 3.1 times higher in the MCAD
deficiency cohort (95% confidence interval, 2.4–4.1)
(Table 2). On an absolute (IRD) scale, during the highest
risk period of six to 12 months of age, children with MCAD
deficiency experienced approximately 1.7 additional visits
per child per year relative to the screen negative cohort
(95% confidence interval, 1.0–2.4), translating to approximately 0.9 additional ED visits per child during that
6 month period. By the time children were 4 years of age or
older, the IRR for ED visits was 1.7 for the MCAD
deficiency group and was still statistically significant (95%
confidence interval, 1.1–2.6), while the IRD reflected 0.3
additional visits per child per year and was not statistically
significant (95% confidence interval, − 0.03-0.7).
Inpatient hospitalizations

Confidence intervals around the estimated rates of inpatient hospital care for children with MCAD deficiency
were wide, reflecting large random variation due to the
small numbers of visits in this small cohort (Fig. 1).
Aligned with the results for ED visits, children with
MCAD deficiency experienced the highest rates of inpatient hospitalization from six to 12 months of age, at
0.6 visits per child per year, or, on average, one hospital
admission per three children with MCAD deficiency
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Fig. 1 Rates of healthcare encounters by health service type (per child per year)

during that 6 month period. After 12 months of age,
rates of hospitalization gradually declined in the MCAD
deficiency cohort, to a low of 0.36–0.37 visits per child
per year after 2 years of age. Among children with
MCAD deficiency, the diagnoses that were most commonly documented in association with inpatient hospital
admissions were the underlying fatty acid oxidation disorder and gastroenteritis and colitis. In the screen negative cohort, the rate of inpatient hospitalization was
highest from birth to 6 months of age (0.21 visits per
child per year, or approximately one visit per every 10
children during that 6 month period), declining to 0.06
visits per child per year from six to 12 months of age
and remaining low throughout the remaining age

categories. Within the screen negative cohort, the diagnoses most commonly associated with inpatient hospital
admissions were neonatal jaundice, pneumonia, and
acute bronchiolitis.
Rates of inpatient hospitalization were much higher in
the MCAD deficiency cohort relative to the screen negative cohort on a relative (IRR) scale from the age of
6 months onward (Table 2); children with MCAD deficiency experienced a 1.6 times higher hospitalization
rate from birth to 6 months of age relative to those with
screen negative results (95% confidence interval, 0.8–
3.5), but this increased to a 10.8 times higher rate of
hospital admission from six to 12 months of age (95%
confidence interval, 6.8–18.9) and remained high.
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Table 2 Age-stratified unadjusted relative (rate ratio) and
absolute (rate difference) comparisons of rates of health services
encounters in MCAD deficiency cohort versus screen negative
cohort

significantly higher in the MCAD deficiency cohort relative to the screen negative cohort at all ages with the exception of the period from birth to 6 months of age,
based on both the IRR and IRD.

Outcome
and age
group

Analyses adjusted for covariates

Incidence rate ratio (IRR),
MCAD deficiency cohort
vs. screen negative cohort
(95% CI)

Incidence rate difference
(IRD), MCAD deficiency
cohort vs. screen negative
cohort, per child per year
(95% CI)

Physician encounters
< 6 months

1.2 (1.1, 1.3)

4.2 (2.1, 6.4)

6 to < 12
months

1.6 (1.4, 1.8)

5.8 (4.1, 7.5)

12 to < 18
months

1.3 (1.1, 1.5)

2.9 (1.3, 4.5)

18 to < 24
months

1.7 (1.5, 1.9)

5.0 (3.4, 6.6)

2 to < 3
years

1.4 (1.2, 1.5)

2.0 (1.1, 2.9)

3 to < 4
years

1.5 (1.3, 1.7)

2.4 (1.3, 3.4)

≥ 4 years

1.5 (1.3, 1.7)

2.5 (1.4, 3.6)

< 6 months

1.9 (1.3, 2.7)

0.7 (0.2, 1.2)

6 to < 12
months

3.1 (2.4, 4.1)

1.7 (1.0, 2.4)

12 to < 18
months

2.6 (2.0, 3.5)

1.4 (0.8, 2.1)

18 to < 24
months

2.7 (2.0, 3.7)

1.3 (0.7, 2.0)

2 to < 3
years

2.1 (1.6, 2.9)

0.7 (0.3, 1.1)

3 to < 4
years

2.0 (1.4, 3.0)

0.5 (0.1, 0.9)

≥ 4 years

1.7 (1.1, 2.6)

0.3 (−0.03, 0.7)a

Emergency
department
visits

Inpatient hospitalizations
< 6 months

1.6 (0.8, 3.5)a

0.1 (− 0.1, 0.4)a

6 to < 12
months

10.8 (6.1, 18.9)

0.5 (0.2, 0.9)

12 to < 24
months

9.6 (6.1, 15.0)

0.4 (0.2, 0.6)

2 to < 3
years

10.8 (6.3, 18.7)

0.3 (0.1, 0.5)

≥ 3 years

15.2 (9.7, 23.8)

0.4 (0.2, 0.5)

Difference not statistically significant, p > 0.05; all other rates were statistically
significantly different between the two cohorts
a

However, due to the low frequency of hospitalization in
both cohorts, this translated into, at its peak, an extra
0.5 hospital stays per child per year in the MCAD deficiency cohort relative to the screen negative cohort from
six to 12 months of age (95% confidence interval, 0.2–
0.9) (Table 2). Hospitalization rates were statistically

Results adjusted for covariates were similar to the unadjusted results reported above. Among children under
1 year of age, following adjustment for covariates, overall
rates for all three types of health services remained significantly higher in children with MCAD deficiency relative to children with negative newborn screening results:
physician encounters (adjusted IRR [aIRR]: 1.39 [95%
confidence interval, 1.18–1.65]), ED visits (aIRR: 2.41
[95% confidence interval, 1.59–3.73]), and inpatient hospitalizations (aIRR: 2.87 [95% confidence interval, 1.41–
5.56]) (Table 3). For children 1 year of age and older, the
adjusted IRRs comparing rates of physician encounters
and ED visits in children with MCAD deficiency to
those among screen-negative children were similar to
the findings in younger children: physician encounters
(aIRR: 1.51 [95% confidence interval, 1.22–1.88]), ED
visits (aIRR: 1.98 [95% confidence interval, 1.39–2.89]).
The relative difference in inpatient hospitalization rates
between children with MCADD and those with screen
negative results was much larger for children greater
than or equal to 1 year of age (aIRR: 12.97 [95% confidence interval, 6.96–26.52]) relative to children in the
first year of life (Table 3). In both age groups, preterm
birth (gestational age < 37 weeks) and low birth weight
were statistically significant predictors of higher health
services use. Lower socioeconomic status was a predictor of higher rates of ED visits and hospitalization,
while rural (vs urban) residence was associated with
higher rates of ED use.

Discussion
We found that children diagnosed with MCAD deficiency through newborn screening used physician services, ED care, and were hospitalized at significantly
higher rates compared to a population-based cohort of
children with negative newborn screening results over
the first several years of age. Previous studies have found
that children diagnosed with fatty acid oxidation disorders experience higher rates of health services use relative to children with other inherited metabolic disorders
[33, 34]. Thus, this overall finding was not unexpected.
The higher rate of physician encounters from birth to
1 year of age that we observed among children with
MCAD deficiency relative to the screen negative cohort
might be partially explained by visits required for diagnostic evaluation following a positive newborn screening
result. However, the relative rate of physician encounters
remained similarly elevated throughout the first 4 years.
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Table 3 Age-stratified adjusted incidence rate ratios for the three service types, MCAD deficiency cohort versus screen negative
comparison cohort
Adjusted incidence rate ratio (95% CI)
≥1 year of age

< 1 year of age
Physician visits

ED visits

Hospitalizations

Physician visits

ED visits

Hospitalizations

MCAD deficiency

1.39 (1.18–1.65)

2.41 (1.59–3.73)

2.87 (1.41–5.56)

1.51 (1.22–1.88)

1.98 (1.39–2.89)

12.97 (6.96–26.52)

Screen negative

Reference

Reference

Reference

Reference

Reference

Reference

0.92 (0.91–0.92)

0.86 (0.85–0.86)

0.76 (0.75–0.77)

0.91 (0.91–0.92)

0.86 (0.85–0.87)

0.78 (0.77–0.80)

Reference

Reference

Reference

Reference

Reference

Reference

Cohort

Sex
Female
Male
Season of birth
Jan. – Apr.

Reference

Reference

Reference

Reference

Reference

Reference

May – Aug.

1.01 (1.00–1.01)

1.04 (1.03–1.05)

0.98 (0.96–1.00)

0.96 (0.95–0.96)

0.95 (0.95–0.96)

0.94 (0.92–0.97)

Sept. – Dec.

1.00 (0.99–1.00)

1.02 (1.00–1.03)

1.08 (1.06–1.11)

1.00 (0.99–1.00)

1.00 (0.99–1.01)

< 2500 g

1.75 (1.74–1.77)

1.04 (1.02–1.06)

2.14 (2.08–2.21)

1.13 (1.12–1.14)

1.03 (1.01–1.05)

1.59 (1.51–1.66)

≥ 2500 g

Reference

Reference

Reference

Reference

Reference

Reference

< 37 weeks

1.57 (1.56–1.58)

1.23 (1.21–1.26)

2.65 (2.57–2.73)

1.09 (1.09–1.10)

1.17 (1.15–1.19)

1.42 (1.36–1.48)

≥ 37 weeks

Reference

Reference

Reference

Reference

Reference

Reference

‘Lower’

1.00 (1.00–1.00)

1.23 (1.22–1.24)

1.09 (1.07–1.11)

0.96 (0.96–0.97)

1.12 (1.11–1.13)

1.10 (1.08–1.13)

‘Higher’

Reference

Reference

Reference

Reference

Reference

Reference

Rural

0.79 (0.78–0.79)

2.34 (2.30–2.37)

1.16 (1.13–1.20)

0.73 (0.72–0.73)

2.28 (2.25–2.31)

1.15 (1.11–1.20)

Urban

Reference

Reference

Reference

Reference

Reference

Reference

1.03 (1.00–1.05)

Birth weight

Gestational age

Socioeconomic status

Urban-rural status

This can be explained by the fact that young children
with MCAD deficiency have short fasting limits and are
monitored closely via follow-up visits in the metabolic
clinic. ED services and inpatient hospitalizations are necessary for children with MCAD deficiency during times
of intercurrent illness or for the prevention or treatment
of acute crises.
The relatively high use of services in this population
reflects the direct costs of effective disease management. Studies conducted in Australia and the
Netherlands that compared healthcare service use and
costs for individuals with MCAD deficiency who were
born prior to screening and identified clinically with
those identified by newborn screening found much
lower costs in the newborn screening-identified cohorts [12, 35]. Similarly, a US economic evaluation
that incorporated primary data from a chart review
into a simulation model predicted far lower costs for
the treatment of MCAD deficiency and associated sequelae among children identified by screening [16].
Consequently, it can be presumed that health services
use for surviving children with MCAD deficiency

would have been even higher than observed if expanded newborn screening had not been introduced
in 2006 in Ontario.
To our knowledge this is the first North American
study to quantify the frequency and patterns of health
services use in young children with MCAD deficiency in
comparison with unaffected children (those in the general population who received negative newborn screening results). In addition to the studies described above
that compared actual or estimated health services use
and costs for children diagnosed with MCAD deficiency
clinically versus through newborn screening, additional
studies have examined use of hospital and specialist care
for children with inherited metabolic disorders overall
but have not compared those patterns with use by unaffected children and have not reported use separately
for children with MCAD deficiency [33, 34].
These findings are important for understanding the impact of this rare inherited metabolic disease on families,
healthcare providers, and systems of care. For example, we
found that the highest rates of ED visits and inpatient hospitalizations among children with MCAD deficiency
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identified through newborn screening occurred from
6 months to 2 years of age, which supports previous evidence documenting the highest risk age groups for metabolic decompensation [3]. Families of children with
MCAD deficiency can be reassured that ED visit rates declined after age two, to less than one visit per year on average by age three, corroborating and extending newborn
screening long-term follow-up studies [33, 35]. Similarly, absolute rates of hospitalization declined over time, to fewer
than 0.4 visits per child per year after age two. Following this
cohort as children age into later childhood and eventually
adulthood could contribute to our currently limited understanding of the longer term healthcare needs of this population [36, 37].
An important limitation of our study was that our analysis of physician encounters did not allow us to distinguish between outpatient and inpatient physician care,
due to incomplete information about the location of care
in the OHIP database. Thus, in our study, the physician
encounter outcome was conflated with the other two
outcomes and does not have a straightforward meaning
for families and providers who may associate the concept of physician encounters with outpatient care. The
impact of this limitation on our findings is particularly
challenging to estimate because in Ontario, pediatric
specialists based at the tertiary care hospitals do not bill
the public insurance plan (OHIP) on a fee-for-service
basis. While such specialists do “shadow bill” for tracking purposes, it may be incomplete and, thus, inpatient
physician care is likely partially but not fully included in
our physician encounter outcome. While we counted ED
visits that led to an inpatient admission as part of both
outcomes, this overlap appropriately reflects both concepts of a visit to the ED and a hospital stay. Transfers
of care from one hospital to another were not distinguished from other hospital stays and may have resulted
in an overestimation of the number of new inpatient admissions. A related limitation is that while our exclusion
of laboratory billings from the OHIP database served the
purpose of ensuring that our physician encounter outcome was specific to encounters involving interactions
between patients and physicians (rather than billings
that were specific to laboratory analyses), we are unable
to quantify from our study the impact of such services
on the health care system.
A limitation of our reliance on routinely-collected healthcare administrative data was our inability to fully characterize
important clinical and psychosocial variables that may impact healthcare utilization. Thus, we were unable to definitively distinguish the roles of factors related to disease
severity, patient co-morbidity, and/or parental perception of
need as possible determinants of care for children with
MCAD deficiency. We did gain some insight into factors affecting health care use through the standard administrative
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data-based documentation of reasons prompting ED visits
and diagnoses associated with inpatient stays. Symptoms of
acute infectious illnesses were the most commonly documented reasons prompting ED visits among children with
MCAD deficiency, which aligned with the reasons for ED
visits in the screen negative cohort, and is consistent with
the use of ED services during intercurrent illness to prevent
or to treat acute metabolic crises. The most common diagnoses associated with inpatient hospital admissions for children with MCAD deficiency were the underlying metabolic
disorder, and gastroenteritis and colitis, which is consistent
with more severe disease-specific exacerbations prompting
hospital stays for children with MCAD deficiency. This contrasts with the diagnoses associated with hospital admissions
in the screen negative cohort (i.e., neonatal jaundice and
acute respiratory infections). A related question not tackled
in our research is the impact of geography in relation to access to care; patients who reside near a metabolic centre
may experience a different threshold to receive ED care and/
or to be admitted to hospital.
A further limitation of our study was that we were unable to assess a possible association of medical encounters
with genotype or with other potential indicators of disease
severity, for example newborn screening analytes, particularly octanoylcarnitine (C8). While correlations among
genotype, biochemical phenotype, and the risk of metabolic
crises for MCAD deficiency are not fully established, newborn screening has detected asymptomatic patients with
genotypes and/or screening C8 levels that are predictive of
milder disease [18, 19, 21, 38]. Metabolic physicians may
thus take such indicators into account, particularly when
providing guidance to parents about using ED services to
prevent crises during minor illnesses.
Studies that link clinical data to healthcare administrative
data could help to address these limitations, to better
understand how disease severity and the receipt of interventions are associated with health services use, to incorporate additional outcomes, including health economic and
patient/family-reported outcomes, and to investigate the
nature of health services received in finer detail (e.g., specialist physician and allied health professional care). This is
likely to require large collaborative data collection initiatives, such as the US Inborn Errors of Metabolism Information System (IBEM-IS) for newborn screening long-term
follow-up (1893 participants enrolled to date at 30 centres
across 21 states) [39, 40] and the clinical data component
of the Canadian Inherited Metabolic Diseases Research
Network (> 700 participants enrolled to date at 13 centres
across 7 provinces) [41].

Conclusions
This study confirms that young children with MCAD deficiency use health services at higher rates relative to children
in the general population. However, reassuringly, rates of
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health service use gradually diminish in this population
after 24 months of age. Understanding patterns of health
care use for children with conditions targeted by newborn
screening can assist families, healthcare providers and policy decision-makers in managing expectations, providing
reassurance about prognosis, and informing planning for
the needs of affected children.
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